102 related articles for article (PubMed ID: 1999085)
1. Use of angiotensin-converting-enzyme inhibitors in the management of renal disease.
Asher JP; Murray KM
Clin Pharm; 1991 Jan; 10(1):25-31. PubMed ID: 1999085
[TBL] [Abstract][Full Text] [Related]
2. Clinical use of angiotensin-converting enzyme inhibitors in patients with renal impairment.
Elliott HL
Blood Press Suppl; 1994; 2():31-4. PubMed ID: 8061843
[TBL] [Abstract][Full Text] [Related]
3. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme inhibitors in diabetes: effect on the kidney and on blood pressure.
Björck S; Aurell M
J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S59-63. PubMed ID: 16989067
[TBL] [Abstract][Full Text] [Related]
5. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN
Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
[TBL] [Abstract][Full Text] [Related]
6. How much must blood pressure be reduced in order to obtain the remission of chronic renal disease?
Pisoni R; Remuzzi G
J Nephrol; 2000; 13(3):228-31. PubMed ID: 10928301
[TBL] [Abstract][Full Text] [Related]
7. Ace inhibition in renal disease: risks and benefits.
Campanacci L; Fabris B; Fischetti F; Bardelli M; Vran F; Carretta R
Clin Exp Hypertens; 1993; 15 Suppl 1():173-86. PubMed ID: 8513308
[TBL] [Abstract][Full Text] [Related]
8. Converting enzyme inhibitors and calcium antagonists in the long-term treatment of hypertension in chronic renal failure.
Lenz T; August P
Wien Klin Wochenschr; 1990 May; 102(11):315-9. PubMed ID: 2195780
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal evaluation of renal function in non-insulin-dependent diabetic patients with early nephropathy: effects of angiotensin-converting enzyme inhibition.
Vora JP; Leese GP; Peters JR; Owens DR
J Diabetes Complications; 1996; 10(2):88-93. PubMed ID: 8777336
[TBL] [Abstract][Full Text] [Related]
10. [Progression of chronic renal insufficiency and its prevention using angiotensin converting enzyme inhibitors and angiotensin antagonists].
Tesar V
Vnitr Lek; 2003 May; 49(5):365-9. PubMed ID: 12908169
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency.
Pisoni R; Faraone R; Ruggenent P; Remuzzi G
J Nephrol; 2002; 15(4):428-30. PubMed ID: 12243375
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation.
Kanno Y; Okada H; Yamaji Y; Nakazato Y; Suzuki H
QJM; 2005 Mar; 98(3):199-203. PubMed ID: 15728401
[TBL] [Abstract][Full Text] [Related]
13. Advances in the treatment of diabetic renal disease: focus on losartan.
Rayner B
Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency.
Tong PC; Ko GT; Chan WB; Ma RC; So WY; Lo MK; Lee KF; Ozaki R; Chow CC; Cockram CS; Chan JC
Diabetes Obes Metab; 2006 May; 8(3):342-7. PubMed ID: 16634995
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin converting enzyme inhibitors and renal function.
Mimran A; Ribstein J
J Hypertens Suppl; 1989 Sep; 7(5):S3-9. PubMed ID: 2681604
[TBL] [Abstract][Full Text] [Related]
17. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic interventions for nephropathy in type I diabetes mellitus.
Breyer JA
Semin Nephrol; 1997 Mar; 17(2):114-23. PubMed ID: 9148377
[TBL] [Abstract][Full Text] [Related]
19. Deletion insertion polymorphism of the angiotensin converting enzyme gene and progression of diabetic nephropathy.
Björck S; Blohmé G; Sylvén C; Mulec H
Nephrol Dial Transplant; 1997; 12 Suppl 2():67-70. PubMed ID: 9269704
[TBL] [Abstract][Full Text] [Related]
20. ACE-I and ARBs in early diabetic nephropathy.
Mauer M; Zinman B; Gardiner R; Drummond KN; Suissa S; Donnelly SM; Strand TD; Kramer MS; Klein R; Sinaiko AR
J Renin Angiotensin Aldosterone Syst; 2002 Dec; 3(4):262-9. PubMed ID: 12584670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
